FDA Clears Rheumatoid Dx Test by Bio-Rad, Axis-Shield | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories and Axis-Shield today announced the US Food and Drug Administration has cleared Bio-Rad's BioPlex 2200 Anti-CCP test for the early detection of rheumatoid arthritis.

The test, which is based on Axis-Shield's proprietary anti-CCP technology, is now being launched in the US. The test was made available outside the US earlier this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.